MDCX Medicus Pharma Ltd Total Asset Value of Company

MDCX (Medicus Pharma Limited) - company brandmark

The price trajectory of Medicus Pharma Ltd. (MDCX) shown below demonstrates total assets amounting to 17.59. Business development relies on external research investments, as the company does not yet generate its own profits. Capitalization growth depends on progress in skin cancer therapy, rendering the company independent of market cycles. Scientific potential is expanding through partnerships with laboratories to implement innovative drug delivery methods.

MDCX (Medicus Pharma Ltd.) Company Total Assets history from 11/15/2024 to 10/30/2026

Analytical breakdowns and data insights for company Medicus Pharma Limited (MDCX)

- stock quotes and analyst forecast:
Share Price medicuspharma.com|MDCX - Price Target Chart
- market capitalization data:
Market Valuation Medicus Pharma Corp|MDCX - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Medicus Pharma|MDCX - Book Capitalization|Market Capitalization to Book Value Ratio medicuspharma.com|MDCX - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Medicus Pharma Ltd.|MDCX - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Medicus Pharma Corp|MDCX - Company Aggregate Debts|Debts to Book Capitalization Medicus Pharma Corp|MDCX - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Medicus Pharma|Interim Coverage Ratio medicuspharma.com
- net income and valuation multiples indicators:
MDCX - Company Net Income
Fundamental valuation:Medicus Pharma Ltd.
Manufactured products of Medicus Pharma Ltd.

Amidst fierce competition in the injectable oncology niche, Medicus Pharma Ltd. (MDCX) is forced to optimize resources to compete with more affordable forms of therapy. The trend in total assets, calculated reverse-engineered via ROA, reflects the actual scale of the business and the impact of currency fluctuations on assets, allowing investors to assess capital management efficiency and the risks of capital freezing during operational expansion.

Key competitors

Total Business Assets KRYS|Aggregate Company Assets Apogee Therapeutics, Inc.|Arcutis - Total Asset Value of Company|Company Total Assets VCEL|ORKA (Oruka Pharma) - Aggregate Asset Value|Company Total Assets SMTI (Sanara MedTech)|Company Total Assets DBV Tech DBVT|SLSN - Aggregate Company Assets|Aggregate Asset Value DERM (Journey Medical)|Forte Biosciences, Inc (FBRX) - Aggregate Company Assets|Cumulative Company Assets Empro Corporation|SLGL (Sol-Gel Technologies) - Company Total Assets|Company Total Assets Revive Pro Care|Cumulative Company Assets VRCA (Verrica Pharmaceuticals)|HOTH (hoththerapeutics.com) - Aggregate Asset Value|Aggregate Company Assets Biofrontera BFRI|Company Total Asset Base VYNE Therapeutics, Inc. (VYNE)|SNOA - Aggregate Company Assets|QNRX - Company Total Assets|AZTR: Company Total Assets|DRMA - Company Total Asset Base|Aggregate Company Assets Elevai Skincare|Total Business Assets RVNC (Revance Therapeutics Inc)